Conclusions Genetic deletion or pharmacological inhibition of NOX2 sensitized AML cells to daunorubicin induced killing in hypoxic environments. NOX2 may thus be a target for overcoming chemoresistance in AML cells in the hypoxic bone marrow environment.

Support This work was supported by Assar Gabrielsson’s Foundation (FB19-64) and other grants used by the research group.

Disclosure Information S. Paul: None. H. Grauers Wiktorn: E. Ownership Interest (stock, stock options, patent or other intellectual property); Modest; Patent. R. Kiffin: None. K. Hellstrand: E. Ownership Interest (stock, stock options, patent or other intellectual property); Modest; Patent. A. Martner: E. Ownership Interest (stock, stock options, patent or other intellectual property); Modest; Patent.

P03.28 STRUCTURAL CHARACTERISTICS IN TUMOR AND LYMPH NODES AS PREDICTORS OF 3-YEAR METASTASIS-FREE SURVIVAL IN SURGICALLY TREATED NSCLC

L. Sellmer*, J. Kovacs, J. Neumann, R. Kiefl, D. Kauffmann-Guerrero, A. Tufman. 1Department of Thoracic Oncology, Hospital of the Ludwig-Maximilians University, Munich, Germany; 2Department of Thoracic Surgery, Hospital of the Ludwig-Maximilians University, Munich, Germany; 3Department of Pathology, Ludwig-Maximilians University, Munich, Germany

Materials and methods Internal hospital databases were screened for NSCLC patients fulfilling inclusion criteria. Data on patients age, sex, surgery type, (neo)adjuvant therapy, tumor characteristics and time and location of relapse was extracted. FFPE tissue blocks of primary tumor, affected and unaffected lymph nodes in patients with and without 3-year metastasis-free survival.

Results A total of 754 NSCLC patients were screened for inclusion criteria. Of these, 71 patients remained in remission for at least 3 years after surgery, and 80 patients had local or systemic relapse within 3 years after surgery. Structural characteristics in tumor and lymph node immune populations differed between patients with and without 3-year metastasis-free survival.

Conclusions Structural characteristics differ between patients with and without relapse. Our findings show that structural markers in tumor and lymph nodes should be taken into account when assessing patient prognosis and relapse risk.